IL18 and prostate carcinoma: For example, a drug which targets and activates NLRP3 can suppress IL-1β and IL-18 while causing prostate cancer pyroptosis and then limiting the scale and scope of inflammation (Dixon et al., 2012; Li et al., 2020).